{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T12:25:22Z","timestamp":1794918322648,"version":"4.9.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"am","delay-in-days":354,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-14-1-0333"],"award-info":[{"award-number":["W81XWH-14-1-0333"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["T32DK007199"],"award-info":[{"award-number":["T32DK007199"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011022","name":"Vertex Pharmaceuticals Incorporated","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011022","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["MD014726"],"award-info":[{"award-number":["MD014726"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.kint.2024.07.026","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T20:38:25Z","timestamp":1724445505000},"page":"1072-1085","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Differing sensitivities to angiotensin converting enzyme inhibition of kidney disease mediated by APOL1 high-risk variants G1 and G2"],"prefix":"10.1016","volume":"106","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8236-2010","authenticated-orcid":false,"given":"Esilida","family":"Sula Karreci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonako","family":"Jacas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Donovan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Pintye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Wiley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsuzsanna K.","family":"Zsengeller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9973-9731","authenticated-orcid":false,"given":"Johannes","family":"Schlondorff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth L.","family":"Alper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin R.","family":"Pollak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2024.07.026_bib2","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1681\/ASN.2010070730","article-title":"The apolipoprotein L1 (APOL1) gene and nondiabetic nephropathy in African Americans","volume":"21","author":"Freedman","year":"2010","journal-title":"J\u00a0Am Soc Nephrol JASN"},{"key":"10.1016\/j.kint.2024.07.026_bib3","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1681\/ASN.2013010113","article-title":"APOL1 variants associate with increased risk of CKD among African Americans","volume":"24","author":"Foster","year":"2013","journal-title":"J\u00a0Am Soc Nephrol JASN"},{"key":"10.1016\/j.kint.2024.07.026_bib4","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1056\/NEJMoa1310345","article-title":"APOL1 risk variants, race, and progression of chronic kidney disease","volume":"369","author":"Parsa","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2024.07.026_bib5","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1126\/science.1193032","article-title":"Association of trypanolytic ApoL1 variants with kidney disease in African Americans","volume":"329","author":"Genovese","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.kint.2024.07.026_bib6","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/nrneph.2013.34","article-title":"APOL1 variants and kidney disease in people of recent African ancestry","volume":"9","author":"Genovese","year":"2013","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.kint.2024.07.026_bib7","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s00439-010-0861-0","article-title":"Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene","volume":"128","author":"Tzur","year":"2010","journal-title":"Hum Genet"},{"key":"10.1016\/j.kint.2024.07.026_bib8","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.semnephrol.2015.04.008","article-title":"APOL1 kidney disease risk variants\u2014an evolving landscape","volume":"35","author":"Dummer","year":"2015","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.kint.2024.07.026_bib9","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.tem.2016.02.002","article-title":"Apolipoprotein L1 and kidney disease in African Americans","volume":"27","author":"Friedman","year":"2016","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.kint.2024.07.026_bib10","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.048952","article-title":"Recessive, gain-of-function toxicity in an APOL1 BAC transgenic mouse model mirrors human APOL1 kidney disease","volume":"14","author":"McCarthy","year":"2021","journal-title":"Dis Model Mech"},{"key":"10.1016\/j.kint.2024.07.026_bib11","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1681\/ASN.V12122832","article-title":"ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results","volume":"12","author":"Ruggenenti","year":"2001","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2024.07.026_bib12","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1056\/NEJMoa053107","article-title":"Efficacy and safety of benazepril for advanced chronic renal insufficiency","volume":"354","author":"Hou","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2024.07.026_bib13","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1056\/NEJMoa2210639","article-title":"Renin\u2013angiotensin system inhibition in advanced chronic kidney disease","volume":"387","author":"Bhandari","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2024.07.026_bib14","doi-asserted-by":"crossref","first-page":"797","DOI":"10.2353\/ajpath.2009.080227","article-title":"Podocyte repopulation contributes to regression of glomerular injury induced by ACE inhibition","volume":"174","author":"Macconi","year":"2009","journal-title":"Am J Pathol"},{"key":"10.1016\/j.kint.2024.07.026_bib15","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1093\/ndt\/gfl495","article-title":"Angiotensin converting enzyme inhibition prevents development of collapsing focal segmental glomerulosclerosis in Thy-1.1 transgenic mice","volume":"21","author":"Smeets","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2024.07.026_bib16","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1093\/ndt\/16.5.961","article-title":"Effect of Lisinopril on the progression of renal insufficiency in mild proteinuric non-diabetic nephropathies","volume":"16","author":"Cinotti","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2024.07.026_bib17","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/j.ekir.2022.04.094","article-title":"Prescribing SGLT2 inhibitors in patients with CKD: expanding indications and practical considerations","volume":"7","author":"Yau","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2024.07.026_bib18","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2024.07.026_bib19","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2024.07.026_bib20","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"The EMPA-KIDNEY Collaborative Group","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2024.07.026_bib21","doi-asserted-by":"crossref","first-page":"F761","DOI":"10.1152\/ajprenal.00552.2020","article-title":"Effects of SGLT2 inhibitor and dietary NaCl on glomerular hemodynamics assessed by micropuncture in diabetic rats","volume":"320","author":"Thomson","year":"2021","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.kint.2024.07.026_bib22","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1007\/s00125-014-3396-4","article-title":"Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration","volume":"57","author":"Skrti\u0107","year":"2014","journal-title":"Diabetologia"},{"key":"10.1016\/j.kint.2024.07.026_bib23","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3317\/jraas.2002.007","article-title":"Acute and long-term effects of ACE inhibition on renal haemodynamics in glomerular and interstitial nephropathies","volume":"3","author":"Guidi","year":"2002","journal-title":"J\u00a0Renin Angiotensin Aldosterone Syst"},{"key":"10.1016\/j.kint.2024.07.026_bib24","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/ki.1990.173","article-title":"Effects of ACE inhibition in normotensive patients with chronic glomerular disease and normal renal function","volume":"38","author":"Bedogna","year":"1990","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2024.07.026_bib25","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/jgm.1317","article-title":"Effect of the content of unmethylated CpG dinucleotides in plasmid DNA on the sustainability of transgene expression","volume":"11","author":"Mitsui","year":"2009","journal-title":"J\u00a0Gene Med"},{"key":"10.1016\/j.kint.2024.07.026_bib26","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1111\/bph.15193","article-title":"The ARRIVE guidelines 2.0: updated guidelines for reporting animal research","volume":"177","author":"Percie du Sert","year":"2020","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.kint.2024.07.026_bib27","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2215\/CJN.06450611","article-title":"Racial differences in the incidence of chronic kidney disease","volume":"7","author":"Muntner","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2024.07.026_bib28","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1097\/01.ASN.0000091586.46532.B4","article-title":"Racial differences in the progression from chronic renal insufficiency to end-stage renal disease in the United States","volume":"14","author":"Hsu","year":"2003","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2024.07.026_bib29","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1093\/ndt\/gfr796","article-title":"APOL1 allelic variants are associated with lower age of dialysis initiation and thereby increased dialysis vintage in African and Hispanic Americans with non-diabetic end-stage kidney disease","volume":"27","author":"Tzur","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2024.07.026_bib30","doi-asserted-by":"crossref","first-page":"294","DOI":"10.2215\/CJN.15161219","article-title":"APOL1 nephropathy: from genetics to clinical applications","volume":"16","author":"Friedman","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2024.07.026_bib31","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1016\/j.ekir.2023.08.028","article-title":"Novel therapies in APOL1-mediated kidney disease: from molecular pathways to therapeutic options","volume":"8","author":"Vasquez-Rios","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2024.07.026_bib32","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1056\/NEJMoa2202396","article-title":"Inaxaplin for proteinuric kidney disease in persons with two APOL1 variants","volume":"388","author":"Egbuna","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2024.07.026_bib33","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.3390\/genes13081460","article-title":"Molecular dynamic simulation reveals structure differences in APOL1 variants and implication in pathogenesis of chronic kidney disease","volume":"13","author":"Mayanja","year":"2022","journal-title":"Genes"},{"key":"10.1016\/j.kint.2024.07.026_bib34","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1124\/molpharm.121.000236","article-title":"Update on angiotensin II subtype 2 receptor: focus on peptide and nonpeptide agonists","volume":"99","author":"Ranjit","year":"2021","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.kint.2024.07.026_bib35","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.kisu.2021.11.002","article-title":"The renin-angiotensin system biomolecular cascade: a 2022 update of newer insights and concepts","volume":"12","author":"Ferrario","year":"2022","journal-title":"Kidney Int Suppl (2011)"},{"key":"10.1016\/j.kint.2024.07.026_bib36","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1172\/JCI1885","article-title":"Cardiac-specific overexpression of angiotensin II AT2 receptor causes attenuated response to AT1 receptor-mediated pressor and chronotropic effects","volume":"101","author":"Masaki","year":"1998","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2024.07.026_bib37","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1161\/01.HYP.0000050101.90932.14","article-title":"Cardiac angiotensin II type 2 receptor activates the kinin\/NO system and inhibits fibrosis","volume":"41","author":"Kurisu","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.kint.2024.07.026_bib38","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00424-022-02779-4","article-title":"Renal angiotensin I-converting enzyme-deficient mice are protected against aristolochic acid nephropathy","volume":"475","author":"Juretzko","year":"2023","journal-title":"Pflugers Arch"},{"key":"10.1016\/j.kint.2024.07.026_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2020.111119","article-title":"The angiotensin-(1-12)\/chymase axis as an alternate component of the tissue renin angiotensin system","volume":"529","author":"Ferrario","year":"2021","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.kint.2024.07.026_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0221957","article-title":"Hypertensive APOL1 risk allele carriers demonstrate greater blood pressure reduction with angiotensin receptor blockade compared to low risk carriers","volume":"14","author":"Cunningham","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2024.07.026_bib41","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11906-011-0237-4","article-title":"Target organ damage in African American hypertension: role of APOL1","volume":"14","author":"Freedman","year":"2012","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.kint.2024.07.026_bib42","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/j.jacc.2017.01.040","article-title":"Apolipoprotein L1 variants and blood pressure traits in African Americans","volume":"69","author":"Nadkarni","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.kint.2024.07.026_bib43","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1111\/febs.13706","article-title":"Structural characterization of the C-terminal coiled-coil domains of wild-type and kidney disease-associated mutants of apolipoprotein L1","volume":"283","author":"Sharma","year":"2016","journal-title":"FEBS J"},{"key":"10.1016\/j.kint.2024.07.026_bib44","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.25461","article-title":"APOL1 renal risk variants have contrasting resistance and susceptibility associations with African trypanosomiasis","volume":"6","author":"Cooper","year":"2017","journal-title":"eLife"},{"key":"10.1016\/j.kint.2024.07.026_bib45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005833","article-title":"Candidate gene polymorphisms study between human African trypanosomiasis clinical phenotypes in Guinea","volume":"11","author":"Kabor\u00e9","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.kint.2024.07.026_bib46","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1073\/pnas.1421953112","article-title":"Human trypanolytic factor APOL1 forms pH-gated cation-selective channels in planar lipid bilayers: relevance to trypanosome lysis","volume":"112","author":"Thomson","year":"2015","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.kint.2024.07.026_bib47","doi-asserted-by":"crossref","first-page":"E2130","DOI":"10.1073\/pnas.1400699111","article-title":"Evolution of the primate trypanolytic factor APOL1","volume":"111","author":"Thomson","year":"2014","journal-title":"Proc Natl Acad Sci. U S A"},{"key":"10.1016\/j.kint.2024.07.026_bib48","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1146\/annurev-physiol-021119-034345","article-title":"APOL1 and kidney disease: from genetics to biology","volume":"82","author":"Friedman","year":"2020","journal-title":"Annu Rev Physiol"},{"key":"10.1016\/j.kint.2024.07.026_bib49","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1681\/ASN.0000000000000094","article-title":"Clinical and genetic characteristics of CKD patients with high-risk APOL1 genotypes","volume":"34","author":"Elliott","year":"2023","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2024.07.026_bib50","article-title":"Phenome-wide analysis of APOL1 risk variants reveals associations between one combination of haplotypes and multiple disease phenotypes in addition to chronic kidney disease","author":"Adamson","year":"2023","journal-title":"medRxiv. 23285950"},{"key":"10.1016\/j.kint.2024.07.026_bib51","doi-asserted-by":"crossref","first-page":"F1039","DOI":"10.1152\/ajprenal.00126.2024","article-title":"SGLT2 inhibitors: not every drug has the same effect","volume":"326","author":"Staruschenko","year":"2024","journal-title":"Am J Physiol-Ren Physiol"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253824005647?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253824005647?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T20:56:11Z","timestamp":1735332971000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253824005647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S0085253824005647"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2024.07.026","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Differing sensitivities to angiotensin converting enzyme inhibition of kidney disease mediated by APOL1 high-risk variants G1 and G2","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2024.07.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2024.09.003","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier, Inc., on behalf of the International Society of Nephrology.","name":"copyright","label":"Copyright"}]}}